Skip to main content

Voluntary Medical Male Circumcision

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Impact Therapeutics
Impact TherapeuticsChina - Shanghai
1 program
Compensation for transport costN/A1 trial
Active Trials
NCT01857700Completed1,504Est. Mar 2014
Aurum Biosciences
Aurum BiosciencesUK - Glasgow
1 program
Text-based VMMC follow-upN/A1 trial
Active Trials
NCT04327271Completed1,093Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Aurum BiosciencesText-based VMMC follow-up
Impact TherapeuticsCompensation for transport cost

Clinical Trials (2)

Total enrollment: 2,597 patients across 2 trials

NCT04327271Aurum BiosciencesText-based VMMC follow-up

Two-way Texting for VMMC Follow-up in Republic of South Africa

Start: Jun 2021Est. completion: Mar 20221,093 patients
N/ACompleted
NCT01857700Impact TherapeuticsCompensation for transport cost

Economic Compensation to Increase Demand for Voluntary Medical Male Circumcision

Start: Jun 2013Est. completion: Mar 20141,504 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.